Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN N UNGAR

Allopathic & Osteopathic Physicians Dermatology

NPI
1912435462
CMS profile
8807563
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$44,934.85

243 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $39,062.50 15
Food and Beverage $4,607.20 225
Travel and Lodging $1,265.15 3

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN N UNGAR

NPI 1912435462 · CMS profile ID 8807563

Allopathic & Osteopathic Physicians / Dermatology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912435462?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN N UNGAR, NPI 1912435462, CMS profile ID 8807563. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912435462?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BENJAMIN N UNGAR, NPI 1912435462, CMS profile ID 8807563. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912435462?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BENJAMIN N UNGAR, NPI 1912435462, CMS profile ID 8807563, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1912435462?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

243 matching records · $44,934.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 243 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 243.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $30.0010/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101637630 CMS
E.R. Squibb & Sons, L.L.C. $99.6710/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101637626 CMS
Eli Lilly and Company $14.0510/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136010193 CMS
Eli Lilly and Company $53.8810/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136065126 CMS
Eli Lilly and Company $151.1710/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136077199 CMS
LEO Pharma Inc. $25.7810/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152654493 CMS
Lilly USA, LLC $13.3110/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136065989 CMS
Regeneron Healthcare Solutions, Inc. $132.3410/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114229616 CMS
Lilly USA, LLC $170.9810/23/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155177113 CMS
PFIZER INC. $21.0410/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132091646 CMS
Galderma Laboratories, L.P. $19.0410/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145333255 CMS
Arcutis Biotherapeutics, Inc. $25.0610/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121037014 CMS
Dermavant Sciences, Inc. $25.8610/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127943004 CMS
Lilly USA, LLC $0.6310/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136065987 CMS
Lilly USA, LLC $0.5010/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136066921 CMS
Lilly USA, LLC $1.4710/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136068198 CMS
Lilly USA, LLC $9.4610/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136077201 CMS
ABBVIE INC. $17.6110/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106259924 CMS
Arcutis Biotherapeutics, Inc. $24.1110/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121037008 CMS
Lilly USA, LLC $8.2810/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136065822 CMS
Regeneron Healthcare Solutions, Inc. $25.2310/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114229609 CMS
ABBVIE INC. $8.5710/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106259922 CMS
Arcutis Biotherapeutics, Inc. $22.7409/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121037010 CMS
GENZYME CORPORATION $12.5609/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139921282 CMS
ABBVIE INC. $19.7009/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106259920 CMS
Arcutis Biotherapeutics, Inc. $23.4309/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121037006 CMS
Lilly USA, LLC $12.5309/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136077209 CMS
Janssen Biotech, Inc. $32.2309/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078443284 CMS
LEO Pharma Inc. $15.8409/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152654491 CMS
ABBVIE INC. $13.4309/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106259918 CMS
ABBVIE INC. $9.3609/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106259916 CMS
GENZYME CORPORATION $47.3209/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139921254 CMS
LEO Pharma Inc. $25.8709/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152654489 CMS
Janssen Biotech, Inc. $18.1809/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078452071 CMS
ABBVIE INC. $23.8809/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106259914 CMS
ABBVIE INC. $24.1109/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106259912 CMS
LEO Pharma Inc. $23.5208/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152654487 CMS
Lilly USA, LLC $11.5008/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136068206 CMS
Lilly USA, LLC $23.6008/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136077215 CMS
Arcutis Biotherapeutics, Inc. $10.6908/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121037004 CMS
ABBVIE INC. $30.5808/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106259910 CMS
GENZYME CORPORATION $12.9508/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139921248 CMS
PFIZER INC. $24.0808/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132057902 CMS
Lilly USA, LLC $8.7208/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136066927 CMS
ABBVIE INC. $12.4408/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106259908 CMS
Galderma Laboratories, L.P. $23.4708/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145333253 CMS
Lilly USA, LLC $13.6508/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136065834 CMS
GENZYME CORPORATION $20.6608/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139921234 CMS
Janssen Biotech, Inc. $30.3908/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078453150 CMS
Arcutis Biotherapeutics, Inc. $13.4208/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121037002 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $696.21 24
PY2022 $5,995.77 82
PY2023 $18,770.02 127
PY2024 $44,934.85 243
PY2025 $86,787.72 234

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $940.00 1
PY2025 Principal investigator $744,063.30 27
PY2024 Principal investigator $550,098.50 9
PY2023 Principal investigator $122,667.00 2
PY2022 Principal investigator $157,497.38 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $27,021.00 12/22/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140878
Principal investigator 1 SANOFI US SERVICES INC. $19,756.30 12/08/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140870
Principal investigator 1 Incyte Corporation $134,380.00 11/18/2025 Non-covered Recipient Entity
Icahn School of Medicine at Mt. Sinai
Characterizing the Molecular Cutaneous Phenotype of Seborrheic Dermatitis and Treatment Response to Ruxolitinib 1.5 percent Cream No dispute reported 06/30/2026 1240538872
Principal investigator 1 SANOFI US SERVICES INC. $26,840.00 11/10/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140857
Principal investigator 1 SANOFI US SERVICES INC. $31,031.00 11/10/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140865
Principal investigator 1 SANOFI US SERVICES INC. $14,127.00 10/06/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140848
Principal investigator 1 SANOFI US SERVICES INC. $12,811.00 09/15/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140841
Principal investigator 1 SANOFI US SERVICES INC. $21,269.40 09/03/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140838
Principal investigator 1 SANOFI US SERVICES INC. $26,403.50 08/18/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140806
Principal investigator 1 SANOFI US SERVICES INC. $16,630.00 08/18/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140810
Principal investigator 1 SANOFI US SERVICES INC. $20,893.00 07/14/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140776
Principal investigator 1 SANOFI US SERVICES INC. $29,621.50 07/07/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140779
Principal investigator 1 SANOFI US SERVICES INC. $25,539.00 06/16/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140764
Principal investigator 1 SANOFI US SERVICES INC. $26,325.50 06/09/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140757
Recipient PFIZER INC. $940.00 05/30/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760536
Principal investigator 1 SANOFI US SERVICES INC. $12,034.00 05/19/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140768
Principal investigator 1 SANOFI US SERVICES INC. $750.00 05/19/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140772
Principal investigator 1 SANOFI US SERVICES INC. $27,439.00 05/12/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140750
Principal investigator 1 SANOFI US SERVICES INC. $19,669.80 05/05/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140739
Principal investigator 1 SANOFI US SERVICES INC. $4,668.00 04/21/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226140735
Principal investigator 1 SANOFI US SERVICES INC. $26,245.00 04/14/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140729
Principal investigator 1 SANOFI US SERVICES INC. $25,064.60 04/07/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140686
Principal investigator 1 SANOFI US SERVICES INC. $64,128.00 03/24/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140696
Principal investigator 1 SANOFI US SERVICES INC. $17,290.00 03/10/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140885
Principal investigator 1 SANOFI US SERVICES INC. $12,727.20 03/04/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226140699
Principal investigator 1 SANOFI US SERVICES INC. $28,690.00 02/18/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140890
Principal investigator 1 SANOFI US SERVICES INC. $17,679.50 02/04/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226140881
Principal investigator 1 SANOFI US SERVICES INC. $55,030.00 01/24/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140887